Why is Natera stock tumbling today?

Natera stock is tumbling 15.3% in pre-open trading today, hitting $308, after the genetic testing company posted Q3 2026 results that beat on revenue but delivered a far wider-than-expected bottom-line loss, sparking an immediate and sustained selloff in after-hours trading that has rolled into the current pre-market session. The company reported revenue of $794 million for the quarter, up 34% year-over-year and well ahead of the analyst consensus, while also raising its full-year 2026 revenue outlook to above $3 billion — yet none of that was enough to offset investor concern over the profitability miss.

The earnings-per-share shortfall was the central problem: Natera posted a GAAP loss of $0.42 per share, missing the consensus estimate of -$0.27 by $0.15, with higher spending on research, commercial teams, and pharma business investments driving the gap wider than the market had anticipated. Compounding the reaction was the simultaneous announcement that longtime CEO Steve Chapman stepped down and was replaced immediately by Solomon Moshkevich, who had served as President of Clinical Diagnostics — a leadership change that, while internally managed, introduced an element of uncertainty at a sensitive moment. Canaccord Genuity moved quickly to reiterate its Buy rating and $500 price target, describing the company’s growth trajectory as compelling, but the analyst endorsement did little to stem the selling pressure in pre-market hours.

The sector backdrop added to the negative tone. Competitor GRAIL reported its own Q3 results on November 5 and saw its shares fall sharply on a revenue miss, reinforcing broad selling pressure across the liquid biopsy and genetic testing space. Meanwhile, the wider market is offering little cover for Natera specifically — the NASDAQ is up 1.7% today, the S&P 500 is modestly positive, and the Dow Jones is slightly lower, underscoring that today’s decline is driven entirely by company-specific factors rather than any macro headwind.

In sum, the combination of a meaningful EPS miss, elevated operating costs signaling that profitability remains elusive, a CEO transition, and sector-wide weakness in genomic diagnostics peers created a perfect storm of selling pressure — overwhelming an otherwise solid revenue performance and pushing Natera shares to their lowest levels in several weeks, well below the stock’s 52-week high of $437.41.